



**ALEMBIC PHARMACEUTICALS LIMITED**  
 Regd. Office: Alembic Road, Vadodara 390 003  
**UNAUDITED FINANCIAL RESULTS**  
**FOR THE PERIOD ENDED 30TH JUNE, 2014**

Rs. In Lacs

	Particulars	CONSOLIDATED			
		Quarter Ended			Year Ended
		June-14	March-14	June-13	March-14
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>1</b>	<b>(a) Net Sales / Income from Operations</b>				
	Domestic	27,840	24,536	24,120	104,106
	Exports	21,773	21,986	18,757	82,735
	Total	49,613	46,522	42,877	186,841
	Less : Excise Duty	248	189	218	771
	Net Sales / Income from Operations	49,365	46,333	42,659	186,070
	<b>(b) Other Operating Income</b>	63	70	57	251
	<b>Total Income from Operations</b>	<b>49,428</b>	<b>46,403</b>	<b>42,716</b>	<b>186,321</b>
<b>2</b>	<b>Expenses</b>				
	(a) Decrease/(Increase) in stock in trade and work in progress	(2,677)	407	(1,303)	(4,065)
	(b) Consumption of Raw Materials & Packing Materials	14,728	13,088	13,597	55,593
	(c) Purchase of traded goods	5,646	4,128	4,949	19,807
	(d) Employees' Cost	7,561	6,715	5,636	24,700
	(e) Marketing Expense	5,196	3,088	4,378	16,618
	(f) Research and Development Expense	2,953	3,120	2,241	11,643
	(g) Excise Duty	152	62	79	425
	(h) Other Expenditure	6,202	6,666	5,991	25,829
	<b>Total Expenses</b>	<b>39,761</b>	<b>37,274</b>	<b>35,568</b>	<b>150,550</b>
<b>3</b>	<b>Profit from Operations before Other Income, Interest, Depreciation &amp; Exceptional Items</b>	<b>9,667</b>	<b>9,129</b>	<b>7,148</b>	<b>35,771</b>
<b>4</b>	<b>Other Income</b>	<b>18</b>	<b>277</b>	<b>2</b>	<b>319</b>
<b>5</b>	<b>Profit from Ordinary Activities before Interest, Depreciation, &amp; Exceptional Items</b>	<b>9,685</b>	<b>9,406</b>	<b>7,150</b>	<b>36,090</b>
<b>6</b>	Depreciation	1,071	1,099	953	4,049
<b>7</b>	Interest (Net)	56	229	147	981
<b>8</b>	CSR Expense	65	-	-	-
<b>9</b>	<b>Net Profit from Ordinary Activities before Tax</b>	<b>8,493</b>	<b>8,078</b>	<b>6,050</b>	<b>31,060</b>
<b>10</b>	<b>Tax Expense</b>				
	Less : Provision for Current Tax	1,735	1,801	1,329	6,847
	Less/(Add) : Provision for Deferred Tax Liability /(Assets)	293	148	57	663
<b>11</b>	<b>Net Profit from Ordinary Activities after Tax</b>	<b>6,465</b>	<b>6,129</b>	<b>4,664</b>	<b>23,550</b>
<b>12</b>	Share of Profit of Associates	2	-	-	-
<b>13</b>	<b>Net Profit after Tax and share of profit of associates</b>	<b>6,467</b>	<b>6,129</b>	<b>4,664</b>	<b>23,550</b>
<b>14</b>	Paid up Equity Share Capital ( Face value of share ₹ 2/- )	3,770	3,770	3,770	3,770
<b>15</b>	Reserves excluding Revaluation Reserve	-	-	-	63,787
<b>16</b>	Basic & Diluted EPS (Not Annualised)	3.43	3.25	2.47	12.49
	<b>PART- II</b>				
<b>A</b>	<b>Particulars of Shareholding</b>				
<b>1</b>	<b>Public Shareholding</b>				
	- Number of Shares	48777294	48777294	48777294	48777294
	- Percentage of Shareholding	25.87	25.87	25.87	25.87
<b>2</b>	<b>Promoters and Promoter Group Shareholding</b>				
	- Fully Non - Encumbered				
	- Number of Shares	139738620	139738620	139738620	139738620
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13
<b>B</b>	<b>INVESTOR COMPLAINTS</b>	<b>Quarter Ended on 30th June, 2014</b>			
	Pending at the beginning of the quarter			NIL	
	Received during the quarter			5	
	Disposed of during the quarter			5	
	Remaining unresolved at the end of the quarter			NIL	

Rs. in lacs

Particulars		STANDALONE			
		Quarter Ended			Year Ended
		June-14	March-14	June-13	March-14
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>PART- I</b>					
<b>1</b>	<b>(a) Net Sales / Income from Operations</b>				
	Domestic	27,840	24,536	24,120	104,106
	Exports	20,525	21,092	18,725	80,793
	Total	48,365	45,628	42,845	184,899
	Less : Excise Duty	248	189	218	771
	Net Sales / Income from Operations	48,117	45,439	42,627	184,128
	<b>(b) Other Operating Income</b>	63	70	57	251
<b>Total Income from Operations</b>		<b>48,180</b>	<b>45,509</b>	<b>42,684</b>	<b>184,379</b>
<b>2</b>	<b>Expenses</b>				
	(a) Decrease/(increase) in stock in trade and work in progress	(2,677)	407	(1,303)	(4,065)
	(b) Consumption of Raw Materials & Packing Materials	14,728	13,088	13,597	55,593
	(c) Purchase of traded goods	5,646	4,128	4,949	19,807
	(d) Employees' Cost	7,322	6,677	5,636	24,446
	(e) Marketing Expense	4,954	2,934	4,378	16,075
	(f) Research and Development Expense	2,754	2,593	2,070	10,510
	(g) Excise Duty	152	62	79	425
	(h) Other Expenditure	5,972	6,955	5,849	25,686
<b>Total Expenses</b>		<b>38,851</b>	<b>36,844</b>	<b>35,255</b>	<b>148,477</b>
<b>3</b>	<b>Profit from Operations before Other Income, Interest, Depreciation &amp; Exceptional Items</b>	<b>9,329</b>	<b>8,665</b>	<b>7,429</b>	<b>35,902</b>
<b>4</b>	<b>Other Income</b>	<b>18</b>	<b>277</b>	<b>2</b>	<b>319</b>
<b>5</b>	<b>Profit/(Loss) from Ordinary Activities before Interest, Depreciation, &amp; Exceptional Items</b>	<b>9,347</b>	<b>8,942</b>	<b>7,431</b>	<b>36,221</b>
<b>6</b>	Depreciation	1,071	1,099	953	4,049
<b>7</b>	Interest (Net)	56	229	147	981
<b>8</b>	CSR Expense	65	-	-	-
<b>9</b>	<b>Net Profit from Ordinary Activities before Tax</b>	<b>8,155</b>	<b>7,614</b>	<b>6,331</b>	<b>31,191</b>
<b>10</b>	<b>Tax Expense</b>				
	Less : Provision for Current Tax	1,714	1,752	1,327	6,700
	Less /Add : Provision for Deferred Tax Liability/(Assets)	293	148	57	663
<b>11</b>	<b>Net Profit from Ordinary Activities after Tax</b>	<b>6,148</b>	<b>5,714</b>	<b>4,947</b>	<b>23,828</b>
<b>12</b>	Paid up Equity Share Capital ( Face value of share Rs. 2/- )	3,770	3,770	3,770	3,770
<b>13</b>	Reserves excluding Revaluation Reserve	-	-	-	59,199
<b>14</b>	Basic & Diluted EPS (Not Annualised)	3.26	3.03	2.62	12.64
<b>PART- II</b>					
<b>A</b>	<b>Particulars of Shareholding</b>				
<b>1</b>	<b>Public Shareholding</b>				
	- Number of Shares	48777294	48777294	48777294	48777294
	- Percentage of Shareholding	25.87	25.87	25.87	25.87
<b>2</b>	<b>Promoters and Promoter Group Shareholding</b>				
	- Fully Non - Encumbered				
	- Number of Shares	139738620	139738620	139738620	139738620
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13
<b>B</b>	<b>INVESTOR COMPLAINTS</b>	<b>Quarter Ended on 30th June, 2014</b>			
	Pending at the beginning of the quarter	NIL			
	Received during the quarter	5			
	Disposed of during the quarter	5			
	Remaining unresolved at the end of the quarter	NIL			

**Notes :**

- 1 The above results, have been duly reviewed by Statutory Auditors, recommended by the Audit Committee and approved by the Board of Directors. The Company has opted to publish consolidated financial results, pursuant to option made available as per clause 41 of the listing Agreement. The Standalone Financial Results are available on the company's website [www.alembic-india.com](http://www.alembic-india.com).
- 2 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Reporting (AS-17).
- 3 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

**For Alembic Pharmaceuticals Limited**

Place : Vadodara  
Date : 28th July, 2014

**Chirayu Amin**  
**Chairman and Managing Director**

**Visit us at [www.alembic-india.com](http://www.alembic-india.com)**